JP2022512573A5 - - Google Patents

Info

Publication number
JP2022512573A5
JP2022512573A5 JP2021517796A JP2021517796A JP2022512573A5 JP 2022512573 A5 JP2022512573 A5 JP 2022512573A5 JP 2021517796 A JP2021517796 A JP 2021517796A JP 2021517796 A JP2021517796 A JP 2021517796A JP 2022512573 A5 JP2022512573 A5 JP 2022512573A5
Authority
JP
Japan
Prior art keywords
dtt
bont
seq
lysc
shows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512573A (ja
JP7511549B2 (ja
Filing date
Publication date
Priority claimed from GBGB1815817.0A external-priority patent/GB201815817D0/en
Application filed filed Critical
Publication of JP2022512573A publication Critical patent/JP2022512573A/ja
Publication of JP2022512573A5 publication Critical patent/JP2022512573A5/ja
Priority to JP2023185401A priority Critical patent/JP7819168B2/ja
Application granted granted Critical
Publication of JP7511549B2 publication Critical patent/JP7511549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517796A 2018-09-28 2019-09-27 外因性活性化ループを含むクロストリジウム神経毒 Active JP7511549B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023185401A JP7819168B2 (ja) 2018-09-28 2023-10-30 外因性活性化ループを含むクロストリジウム神経毒

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1815817.0A GB201815817D0 (en) 2018-09-28 2018-09-28 Clostridial neurotoxins comprising and exogenous activation loop
GB1815817.0 2018-09-28
PCT/GB2019/052732 WO2020065336A1 (en) 2018-09-28 2019-09-27 Clostridial neurotoxins comprising an exogenous activation loop

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023185401A Division JP7819168B2 (ja) 2018-09-28 2023-10-30 外因性活性化ループを含むクロストリジウム神経毒

Publications (3)

Publication Number Publication Date
JP2022512573A JP2022512573A (ja) 2022-02-07
JP2022512573A5 true JP2022512573A5 (https=) 2022-09-06
JP7511549B2 JP7511549B2 (ja) 2024-07-05

Family

ID=64108972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517796A Active JP7511549B2 (ja) 2018-09-28 2019-09-27 外因性活性化ループを含むクロストリジウム神経毒
JP2023185401A Active JP7819168B2 (ja) 2018-09-28 2023-10-30 外因性活性化ループを含むクロストリジウム神経毒

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023185401A Active JP7819168B2 (ja) 2018-09-28 2023-10-30 外因性活性化ループを含むクロストリジウム神経毒

Country Status (16)

Country Link
US (1) US12589139B2 (https=)
EP (1) EP3856232A1 (https=)
JP (2) JP7511549B2 (https=)
KR (1) KR20210068476A (https=)
CN (1) CN113164565A (https=)
AU (1) AU2019348732C1 (https=)
BR (1) BR112021005017A2 (https=)
CA (1) CA3111962A1 (https=)
EA (1) EA202190889A1 (https=)
GB (1) GB201815817D0 (https=)
IL (1) IL281814A (https=)
MX (1) MX2021003261A (https=)
SG (1) SG11202102323TA (https=)
TW (2) TW202517790A (https=)
UA (1) UA130362C2 (https=)
WO (1) WO2020065336A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
KR20230155007A (ko) 2021-03-30 2023-11-09 입센 바이오팜 리미티드 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소
JP2024513191A (ja) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
CN115785237B (zh) * 2022-09-01 2023-06-16 上海蓝晶生物科技有限公司 一种重组肉毒杆菌毒素及其制备方法
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) * 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
CN116813727B (zh) * 2023-06-08 2025-06-06 苏州德进生物制药有限公司 一种a型肉毒毒素的制备方法及其应用
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
CN118126143B (zh) * 2024-03-14 2025-06-24 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
CN119859174B (zh) * 2025-01-13 2026-03-20 乐普健糖药业(重庆)有限公司 重组肉毒毒素及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
CN1241945C (zh) 1998-05-13 2006-02-15 拜欧特康生化技术开发和咨询有限公司 用于抑制肥大细胞脱粒的杂合蛋白质及其用途
DE69910216T2 (de) 1998-07-22 2004-02-19 Osprey Pharmaceuticals Ltd., Calgary Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
AU2486900A (en) * 1998-12-29 2000-07-31 University Of Georgia Research Foundation, Inc., The Rubredoxin fusion proteins, protein expression system and methods
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
ATE348178T1 (de) 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
AU2005311086B2 (en) 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE518882T1 (de) 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
EP1931379B1 (en) * 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
CN102083451A (zh) * 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
GB0815264D0 (en) * 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
CN105833254A (zh) 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
AU2010236613B2 (en) 2009-04-14 2016-07-07 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
CZ302526B6 (cs) * 2010-05-13 2011-06-29 Zentiva, K.S. Rekombinantní produkce teriparatidu v bakteriích Escherichia coli
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
EP2793934B1 (en) 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
SG11201809903WA (en) 2016-05-16 2018-12-28 Harvard College Method for purification and activation of botulinum neurotoxin
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
WO2019152380A1 (en) 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop

Similar Documents

Publication Publication Date Title
JP2022512573A5 (https=)
Eddleston et al. Molecular profile of reactive astrocytes—implications for their role in neurologic disease
TW200635945A (en) Antibodies against IL-13 receptor alpha 1 and uses thereof
WO2007047829A3 (en) Novel heterodimeric proteins and uses thereof
NO20061026L (no) Nye insulinderivater
WO2005068494A3 (en) Chimera botulinum toxin type e
DE60227064D1 (de) Von rna polymerasen abstammende polypeptide und ihre verwendungen
AR077931A2 (es) Anticuerpos contra la interleuquina-13 humana y usos de los mismos
ATE506374T1 (de) Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen
SI2380592T1 (en) Antagonist antibody directed against calcitonin gene-related peptide
EP1549767A4 (en) MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
Peters et al. Further studies on Pseudomonas aeruginosa LasA: analysis of specificity
CA2208524A1 (en) Delivery of nucleic acid molecules to mucosal tissue
WO2003035679A3 (en) Molecules
Fusi et al. Ribonucleases from the extreme thermophilic archaebacterium S. solfataricus
AU2003265561A1 (en) Chimeric protein
DE19951196A1 (de) Massgeschneiderte Peptidsynthetasen und ihre Verwendung
EP1118669A9 (en) Production of camelid antibodies in plants
WO2009044294A3 (en) Means and methods for the treatment of cataract and presbyopia
WO2001025267A3 (en) Improved ricin-like toxins for treatment of cancer
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
DE602006012065D1 (de) Zusammensetzungen und methoden zur diagnose und behandlung von entzündungen
WO2006020470A3 (en) Promotion of axonal regeneration
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus